Home / Resources / Spravato Billing

Spravato Billing Codes & REMS Requirements: 2026 Guide

By Dynamic Medical Billing Solutions · Updated October 24, 2026 · 7 min read

Spravato (esketamine) is one of the highest-value — and most frequently denied — services a psychiatric practice can bill. The drug is expensive, supervision and observation are paid differently by different payers, and the code set changed on January 1, 2026. This guide covers the current codes, both payer pathways, and the REMS documentation claims depend on.

Why Spravato Billing Breaks So Easily

A single Spravato session ties up an expensive drug, a certified treatment room, and at least two hours of clinician observation. If any element is coded or documented wrong — drug code, units, observation time, authorization — the practice can lose the full cost of that session. The rules also split by payer: Medicare pays one bundled code, while most commercial payers pay drug and clinical time separately. Billing both pathways the same way is the most common reason claims fail.

The 2026 Code Change: J0013 Replaces S0013

Three code facts drive every Spravato claim in 2026:

• Before 2026 — the esketamine drug was billed with HCPCS S0013 to most commercial and Medicaid payers.
• From January 1, 2026 — HCPCS J0013 (esketamine nasal spray, 1 mg) replaces S0013. Units equal total milligrams administered: a 56 mg dose is 56 units, an 84 mg dose is 84 units.
• Medicare exception — J0013 is not payable by Medicare. Medicare pays its own bundled G-codes instead, covered in the next section.

Claims submitted with S0013 for 2026 dates of service are denied as an invalid code. Update your charge master now, and review January-onward denials for rebilling while timely-filing limits still allow it.

Medicare's G-Code Pathway: G2082 and G2083

Service	Typical codes	Billing notes
Spravato session, dose up to 56 mg	G2082	Bundled payment: drug, supervision and 2-hour observation included. No separate E/M.
Spravato session, dose over 56 mg	G2083	The same bundle at the higher dose — typically 84 mg.
Drug code under Medicare	J0013	Not payable by Medicare. This is the commercial and Medicaid drug code.
Observation period	Included in G2082 / G2083	At least 2 hours of direct observation, with start/end times and a discharge assessment documented.
Diagnosis	F33.2 / F32.2	Major depressive disorder, severe (treatment-resistant), as supported by the record.
Prior authorization	PA number on the claim	Obtain authorization before the first session and include the number on the claim.
Drug identifier	11-digit NDC	Report the NDC of the actual devices administered on the drug line.

Medicare pays for Spravato under two bundled HCPCS codes. The bundle includes the drug, the clinician's supervision and the required 2-hour observation — which is why no separate E/M or prolonged-service code is billed to Medicare alongside them. Confirm codes in the current HCPCS book and payer policy before billing.

The Commercial Pathway: J0013 Plus E/M and Prolonged Services

Most commercial and Medicaid payers that do not use the G-codes pay the components separately: the drug via J0013 with units equal to total milligrams, and the evaluation, supervision and observation time through an E/M visit code plus prolonged-service codes where documented time supports them — 99415 and 99416 for clinical staff time, and 99417 (or G2212 for payers that use it) for physician time, per payer policy. Medical necessity rests on the diagnosis: claims should carry F33.2 or F32.2 (major depressive disorder, severe), as supported by the record. See our E/M coding guide for level-selection and time rules.

REMS Requirements That Affect Billing

Spravato is administered only under a Risk Evaluation and Mitigation Strategy (REMS) program. The practice must be a REMS-certified healthcare setting, the patient must be enrolled in REMS, and a healthcare provider must directly observe the patient for at least 2 hours after administration, with a discharge assessment before the patient leaves. These are not just clinical rules — payers audit them. A session billed without documented observation time, a named supervising clinician and a discharge assessment is a denial and recoupment risk. Dosing is by 28 mg devices: 56 mg uses 2 devices, 84 mg uses 3, and claim units and NDC should match the devices documented.

Buy-and-Bill vs. Specialty Pharmacy

How the drug reaches your practice changes your billing workload and cash exposure. There are two models, and the patient's plan may mandate one:

• Buy-and-bill — you purchase from a REMS-certified specialty distributor, hold inventory, and bill the payer for drug and administration. You control scheduling, but carry the cost and denial risk.
• Specialty pharmacy — the pharmacy bills the drug and ships patient-specific doses; the practice bills the administration and observation its payer allows. Less cash at risk, more coordination per session.
• Either way, verify benefits and obtain prior authorization before the first session, and confirm which model the plan requires.
• When your practice bills the drug, include the 11-digit NDC on the drug line and the authorization number on the claim.

Common Spravato Denials and How to Prevent Them

• Invalid drug code — S0013 billed for a 2026 date of service. Update the charge master to J0013 or G2082/G2083.
• Wrong units — J0013 units are total milligrams (56 mg = 56 units), not devices.
• Separate E/M billed with a Medicare G-code — supervision and observation are inside the bundle.
• Missing prior authorization (CO-197) — obtain it before treatment and put the number on the claim.
• Missing or incorrect NDC — report the 11-digit NDC from the actual devices administered.
• Observation not documented — no start/end times, clinician or discharge assessment in the note.

Dedicated denial management helps work the backlog, and a billing audit of Spravato claims usually surfaces unit, code and documentation errors quickly.

Spravato Documentation Checklist

1. Confirm REMS enrollment and a REMS-certified healthcare setting.
2. Obtain prior authorization before the session and record the number for the claim.
3. Document the dose in milligrams and devices (56 mg = 2 devices; 84 mg = 3 devices).
4. Bill the drug correctly: J0013, units = total mg (commercial/Medicaid) or the right G-code (Medicare), plus the 11-digit NDC.
5. Document observation start/end times — at least 2 hours.
6. Name the supervising clinician in the documentation.
7. Complete and document the discharge assessment before the patient leaves.

Practices starting or scaling a Spravato program can hand this workflow to a specialty team. Learn more about our Spravato billing services.

This article is educational and not a substitute for current CPT, NCCI or payer policy.

A Clean Spravato Claim, Step by Step

For a commercial patient receiving 56 mg: verify benefits and prior authorization first, confirm REMS enrollment, then bill J0013 at 56 units with the 11-digit NDC and authorization number on the claim, plus the E/M and any prolonged-service codes the documented time supports. The diagnosis line carries F33.2 or F32.2, as documented.

For a Medicare patient at the same dose, the claim is a single bundled line: G2082, which already includes the drug, supervision and 2-hour observation. The work that gets it paid happens before submission — REMS enrollment, observation start/end times, the supervising clinician and the discharge assessment, all documented and ready if Medicare asks.

Frequently Asked Questions

What code replaced S0013 for Spravato in 2026?

From January 1, 2026, HCPCS J0013 (esketamine nasal spray, 1 mg) replaced S0013 for commercial and Medicaid payers. Units equal the total milligrams administered — a 56 mg dose is 56 units.

Does Medicare pay for J0013?

No. J0013 is not payable by Medicare. Medicare pays bundled codes G2082 (up to 56 mg) and G2083 (over 56 mg), which include the drug, supervision and 2-hour observation — no separate E/M is billed with them.

How long must a patient be observed after Spravato administration?

At least 2 hours, under direct observation by a healthcare provider, in a REMS-certified setting, with a discharge assessment before the patient leaves. Document start and end times — payers audit them.

What diagnosis codes support Spravato claims?

Spravato is used for treatment-resistant depression, so claims typically carry F33.2 or F32.2 — major depressive disorder, severe — as supported by the record, with the prior authorization number and 11-digit NDC on the drug line.

What is the difference between buy-and-bill and specialty pharmacy for Spravato?

Under buy-and-bill, the practice purchases the drug from a REMS-certified specialty distributor and bills the payer for it. Under a specialty-pharmacy model, the pharmacy bills the drug and ships patient-specific doses. The model often depends on the patient's plan.